QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus

Br J Clin Pharmacol. 2011 Nov;72(5):839-41. doi: 10.1111/j.1365-2125.2011.04065.x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arrhythmias, Cardiac / chemically induced*
  • Drug-Related Side Effects and Adverse Reactions*
  • Electrocardiography / methods
  • Female
  • Heart Rate / drug effects*
  • Humans
  • Male
  • United States
  • United States Food and Drug Administration